Arkolith/Insider Trading/ALDX/Form 4

Brady Todd C

President and CEO, DirectorAldeyra Therapeutics, Inc. (ALDX) · full profile →Form 4 · filed Sep 11, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 7, 2023Option exercise(M)192K$0.55$106K1.6M
Sep 7, 2023Tax withholding(F)74K$7.22$533K1.7M
Sep 7, 2023Option exercise(M)48K$0.55$26K1.7M
Sep 7, 2023Option exercise(M)33K$0.55$18K1.7M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 7, 2023Option exercise(M)48K—$00
Sep 7, 2023Option exercise(M)192K—$00
Sep 7, 2023Option exercise(M)33K—$00

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-047530) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Aldeyra Therapeutics, Inc.

Build

Ask your agent about ALDX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000950170-23-047530"
Ask your agent
Use Arkolith to summarize insider buying and selling at Aldeyra Therapeutics, Inc.
over the last 90 days and cite the filings.